biochimica clinica

en_US English
en_US English it_IT Italian

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica 2015; 39(1) 041-047

Published on-line:

February 1, 2015

DOI:

Download in PDF:

Dabigatran e analisi di laboratorio
Dabigatran and laboratory tests

AUTHORS

Roberto Facchinetti1, Barbara Capizzi1, Beatrice Caruso1, Mauro Negri1, Roberto Suppi1, Giulio Molon2, Gian Cesare Guidi1 1Laboratorio Analisi, Azienda Ospedaliera Universitaria Integrata Verona 2Cardiologia, Ospedale Sacro Cuore Negrar, Verona

ABSTRACT

New oral anticoagulants (i.e., dabigatran, rivaroxaban, apixaban) are now available. In using these drugs, routine monitoring of laboratory coagulation tests is not recommended. In some clinical conditions, however, a laboratory evaluation of hemostatic balance may be useful. Tests suggested for laboratory monitoring of dabigatran treatment are thrombin time on undiluted (TT) or diluted (dTT) plasma and ecarin clotting time. On 30 patients taking dabigatran for non valvular atrial fibrillation, we assayed dabigatran levels by dTT, also performing prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and TT. In patients taking dabigatran etexilate 110 mg bis in die and 150 mg bis in die, dTT mean results (10th-90th percentile) were 97 (32-152) and 94 (33-189) μg/L, respectively. In dTT range from 13 to 60 μg/L and >60 μg/L, we obtained 27% and 58% prolonged PT, 64% and 95% prolonged APTT, and 100% and 100% prolonged TT, respectively, showing that for dabigatran TT is a useful screening test.

REFERENCES